Overview: Biotinidase Newborn Screen TestIntroduction: The Biotinidase Newborn Screen Test screens newborns for biotinidase deficiency, which may cause skin rashes or developmental issues if untreated. Aligned with 2023 ACMG guidelines, it uses PCR for high sensitivity, aiding in newborn screening. This test is critical for early diagnosis, treatment, and improving outcomes in molecular pathology for newborns.
Other Names: Biotinidase NBS Assay, Newborn Metabolic Screen.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Newborn screening for biotinidase deficiency began in the 1980s. PCR-based screening emerged in the 1990s, and by the 2000s, high-throughput assays improved early detection.
Purpose: Screens newborns for biotinidase deficiency, guides early biotin supplementation, and prevents developmental issues.
Test Parameters: 1. Biotinidase
Pretest Condition: No fasting required. Collect dried blood spots within 24-48 hours of birth. Report family history of metabolic disorders or newborn symptoms.
Specimen: 3-5 dried blood spots (DBS card). Collect via heel prick. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document family history of biotinidase deficiency or metabolic disorders. Include any newborn symptoms like poor feeding or lethargy.
Consent: Written parental consent required, detailing the tests purpose, implications for early treatment, and potential need for follow-up testing.
Procedural Considerations: Uses PCR to detect biotinidase deficiency. Results are available in 1-2 days, enabling rapid intervention.
Factors Affecting Result Accuracy: Improper collection or delayed transport can degrade samples. Maternal biotin supplementation may affect results.
Clinical Significance: Positive results confirm deficiency, prompting immediate biotin therapy. Negative results support routine monitoring.
Specialist Consultation: Consult a medical geneticist for result interpretation. A pediatrician referral is advised for follow-up care.
Additional Supporting Tests: Biotinidase activity test, genetic testing, or plasma amino acids to confirm deficiency.
Test Limitations: False positives may occur with improper sample handling. Results require confirmatory testing.
References: ACMG Newborn Screening Guidelines, 2023; Pediatrics, Wolf B, 2022.
